Genetically engineered mouse models

$249,241P01FY2015CANIH

Massachusetts General Hospital, Boston MA

Investigators

Linked publications & trials

Paper 39563028 Paper 39138760 Paper 38303726 Paper 37870204 Paper 37824733 Paper 37725979 Paper 37716353 Paper 37194237 Paper 36936071 Paper 36907561 Paper 36870999 Paper 36427266 Paper 36404434 Paper 35849415 Paper 35750648 Paper 35675910 Paper 35666645 Paper 35654978 Paper 35624211 Paper 35624008 Paper 35590035 Paper 35572197 Paper 35417683 Paper 35033904 Paper 35017150 Paper 34890082 Paper 34850166 Paper 34584243 Paper 34446922 Paper 34298912 Paper 34233961 Paper 34183802 Paper 33799709 Paper 33707748 Paper 33687214 Paper 33548389 Paper 33301777 Paper 33282910 Paper 33274611 Paper 33255871 Paper 33240762 Paper 33239433 Paper 33234347 Paper 33103361 Paper 33103128 Paper 33051308 Paper 32881418 Paper 32815324 Paper 32815321 Paper 32555306 Paper 32519463 Paper 32504554 Paper 32484293 Paper 32457507 Paper 32414213 Paper 32394646 Paper 32383351 Paper 32351054 Paper 32299465 Paper 32203281 Paper 32198420 Paper 32178271 Paper 32075753 Paper 32061674 Paper 32038644 Paper 32019882 Paper 32004403 Paper 31852796 Paper 31839905 Paper 31628025 Paper 31533034 Paper 31413142 Paper 31242427 Paper 31092696 Paper 30951671 Paper 30951667 Paper 30949309 Paper 30943406 Paper 30916923 Paper 30889795 Paper 30842671 Paper 30759398 Paper 30637094 Paper 30561734 Paper 30456354 Paper 30445298 Paper 30288631 Paper 30279232 Paper 30257000 Paper 30254196 Paper 30108686 Paper 30082792 Paper 30057404 Paper 29985475 Paper 29975720 Paper 29805987 Paper 29696074 Paper 29533646 Paper 29532035 Paper 29388135

Abstract

PROJECT SUMMARY (See instructions): The utilization of genetically engineered mouse (GEIVI) strains is an integral component of this GTBT P01 program project. The mouse model Core will provide all the necessary expertise, reagents and services for the analysis of exosomal biology with regards to therapeutic applications in GEM models of GBM. The services and reagents provided by this Core will synergize with the individual Projects on the validation and assessment of exosomal-associated molecular biomarkers and the application of cutting edge monitoring technologies for tumor response to therapeutic agents. In addition, the Core will produce and characterize three new GBM GEM strains over the funding period. As such, the Core will support all aspects of the construction of these new transgenic mouse models, including advice, service, technologies and reagents for the optimal design and construction of each specific strain. Using these new strains, the Core will also evaluate and implement new technologies for the detection and monitoring of various exosomal metrics in close relationship with the individual Projects.

View original record on NIH RePORTER →